Air-liquid interface bronchial organoid modeling — from basal stem cell to beating cilia, F508del CFTR disease modeling, and forskolin-swelling readouts for Trikafta-class modulator testing
Airway basal cells are the resident multipotent stem cells of the conducting airway epithelium, marked by cytokeratin-5 (KRT5) and transcription factor TP63. A brief nasal or bronchial brushing during a routine clinical procedure yields thousands of viable basal cells that can be expanded in vitro and used to reconstitute a full, patient-specific airway epithelium — including in individuals whose own CFTR genotype is rare enough that no clinical trial data exists for their specific mutation.
Cell sourcing: • Nasal brushing (cytology-style curette) or bronchoscopic brushing/biopsy — minimally invasive, outpatient, repeatable • Yield: 1,000–50,000 viable epithelial cells per brush; basal fraction enriched by adherent culture selection • Fulcher & Randell (2013) protocol remains the field-standard reference for human bronchial epithelial cell (HBEC) culture
Conditional reprogramming / expansion: • Basal cells cultured on collagen-I coated plastic in bronchial epithelial growth medium (BEGM) or dual-SMAD/Rho-kinase-inhibitor "conditionally reprogrammed cell" (CRC) medium • Y-27632 (ROCK inhibitor) + irradiated 3T3-J2 feeder layer dramatically extends proliferative capacity, allowing population doublings sufficient to generate multiple ALI cultures from a single brushing • Cells retain basal identity (KRT5/TP63) and multipotency through several passages; senescence and loss of differentiation capacity typically emerge by passage 3–4
Biobanking: • Early-passage basal cells cryopreserved in liquid nitrogen, enabling repeated ALI differentiation runs from the same patient over years — critical for longitudinal CFTR modulator response studies
Transwell configuration: • Polyester or PTFE membrane insert, 0.4µm pore diameter, seeded with 1–2×10^5 basal cells on the apical (upper) collagen-coated surface • Both apical and basal chambers initially submerged in proliferation medium until confluence (typically 3–5 days)
Air-lift: • Apical medium is aspirated once the monolayer reaches confluence, exposing the apical surface directly to air while the basal chamber continues to supply nutrients and differentiation medium (e.g., PneumaCult-ALI) • This asymmetric nutrient/oxygen gradient is the key trigger that pushes basal cells toward a pseudostratified, multiciliated differentiation program rather than a simple squamous monolayer • Over the following weeks, the culture self-organizes into distinct basal, ciliated, and secretory compartments — recapitulating native airway histology on a 12mm insert.
Over three to four weeks at air-liquid interface, the initially homogeneous basal cell monolayer diversifies into the full complement of conducting-airway epithelial lineages: ciliated cells bearing hundreds of motile cilia, mucus-secreting goblet cells, club cells that detoxify inhaled xenobiotics and serve as a secondary progenitor pool, and a maintained basal layer. This self-organizing differentiation is driven by Notch lateral-inhibition signaling and is now routinely benchmarked against single-cell RNA-seq atlases of native human airway.
Basal-to-luminal fate decisions: • High Notch activity in a basal cell biases it toward the secretory (club/goblet) lineage; low/inhibited Notch permits the multiciliogenesis program • Lateral inhibition (DLL1/DLL4-Notch1/2/3) creates a "salt-and-pepper" pattern of alternating ciliated and secretory precursors, matching the checkerboard arrangement seen in native bronchial epithelium • The master multiciliogenesis transcription factor FOXJ1, downstream of Multicilin (MCIDAS), drives centriole amplification (up to ~200 basal bodies per cell) and axonemal dynein assembly • MUC5AC (goblet, inflammation-inducible) and MUC5B (predominant baseline gel-forming mucin) mark distinct secretory subpopulations; club cells express SCGB1A1 (secretoglobin/CC10) and retain some basal-like plasticity, able to repopulate the epithelium after injury
Quality control: • Single-cell RNA-seq of mature ALI cultures now closely matches native bronchial brushings (Human Lung Cell Atlas references), validating organoid fidelity for FOXJ1+, MUC5B+, SCGB1A1+, and KRT5+ compartment proportions
Because differentiation trajectory and final cell-type proportions are sensitive to basal cell passage number, feeder-layer conditions, and even donor age, most CFTR functional-testing pipelines run a parallel wild-type control ALI culture alongside every patient-derived line to normalize for batch-to-batch differentiation variability before drawing conclusions about disease or drug response.
A healthy ALI culture becomes visibly and functionally alive: each ciliated cell projects roughly 200 motile cilia that beat 8–15 times per second in a coordinated metachronal wave, propelling the overlying mucus layer unidirectionally across the epithelial surface. This mucociliary escalator is the airway's primary physical clearance mechanism, continuously sweeping inhaled particulates, allergens, and pathogens toward the pharynx to be swallowed or expectorated.
Axoneme structure: • Classic 9+2 microtubule arrangement: nine outer doublets + central pair, driven by outer and inner dynein arms that generate the effective (power) and recovery strokes • ATP-powered dynein walking along adjacent microtubule doublets converts chemical energy into the asymmetric beat cycle: a fast, extended power stroke through the mucus layer followed by a slower, bent recovery stroke within the low-viscosity periciliary layer
Metachronal coordination: • Neighboring cilia do not beat in phase; instead a fixed phase lag between adjacent cilia produces a traveling wave across the epithelial sheet — visually resembling wind moving across a wheat field • This coordination maximizes net fluid transport efficiency and is thought to arise from hydrodynamic coupling between neighboring cilia plus intracellular calcium-wave synchronization • Beat frequency is exquisitely sensitive to periciliary fluid volume/composition, ATP/purinergic signaling (ATP and adenosine act on P2Y2 and A2b receptors to modulate CFTR and ENaC), and temperature
Airway surface liquid architecture: • Periciliary liquid (PCL) layer: low-viscosity "sol" layer, height set by balance of CFTR-mediated Cl⁻/HCO3⁻ secretion and ENaC-mediated Na⁺ (and water) absorption — must match extended cilium length for efficient tip engagement with mucus • Mucus layer: viscoelastic gel dominated by the large, heavily O-glycosylated mucins MUC5AC and MUC5B, floating atop the PCL and physically isolated from direct cilia-base contact • Only cilia tips penetrate into the mucus gel during the power stroke, "grabbing" and advancing it, then disengaging during the low-drag recovery stroke within the PCL — a mechanism that depends critically on correct PCL hydration
Bicarbonate's role: • CFTR-conducted HCO3⁻ is not just a bystander anion — it is required to unpack and hydrate mucin granules as they are released, and to maintain airway surface liquid pH; impaired HCO3⁻ transport produces abnormally viscous, poorly unpacked mucus even before considering the Cl⁻/fluid transport defect.
Deletion of a single phenylalanine at position 508 of the CFTR protein (F508del) is by far the most common CF-causing mutation, present on at least one allele in roughly 90% of people with cystic fibrosis worldwide. The mutant protein misfolds during biogenesis, is retained and degraded by ER quality control, and never reaches the apical membrane in useful quantity — collapsing chloride/bicarbonate secretion, dehydrating the periciliary layer, and producing the thick, static, infection-prone mucus that defines CF airway disease.
CFTR is an ABC-transporter-family chloride/bicarbonate channel: • Domain architecture: two membrane-spanning domains (MSD1/2), two nucleotide-binding domains (NBD1/2) that bind and hydrolyze ATP to gate the channel, and a regulatory (R) domain phosphorylated by PKA • F508del removes a single residue from NBD1, destabilizing the NBD1–MSD2 interface and the overall folding trajectory of the protein during co-translational assembly in the endoplasmic reticulum
CFTR mutation classes (F508del spans several): • Class I: no protein made (nonsense/frameshift) • Class II: protein made but misfolded/degraded — F508del's primary defect; ER quality control (calnexin cycle, ERAD) recognizes the misfolded NBD1 and routes >99% of the protein to proteasomal degradation • Class III: reaches membrane but gating (channel open probability) is defective — F508del's secondary defect, since the small fraction that does escape ER retention still gates poorly • Class IV/V/VI: reduced conductance, reduced synthesis, or reduced membrane stability — F508del also has a mild Class VI component (accelerated turnover at the membrane)
Because F508del carries combined class II (trafficking) + class III (gating) + class VI (stability) defects, effective pharmacological rescue requires a combination approach — correcting folding/trafficking AND potentiating channel gating.
The CF airway phenotype in ALI/organoid culture: • Absent apical Cl⁻/HCO3⁻ secretion + unrestrained ENaC-mediated Na⁺/water hyperabsorption collapses periciliary liquid volume ("low-volume hypothesis," Boucher and colleagues) • PCL height falls below the extended length of cilia, so cilia tips can no longer properly engage and transport the overlying mucus gel — beating continues but achieves little net transport • Reduced HCO3⁻ secretion also leaves mucins poorly unpacked/hyperconcentrated and abnormally acidic ASL, further raising mucus viscoelasticity • Video-tracked mucus transport and particle-tracking microrheology in CF ALI cultures typically show 60–90% reduction in net transport velocity versus matched non-CF cultures — even though raw ciliary beat frequency is only modestly reduced, since it is mucus engagement, not beat rate per se, that fails first • Chronic mucus stasis creates a nutrient-rich, hypoxic biofilm niche that predisposes to recurrent Pseudomonas aeruginosa and Staphylococcus aureus infection, progressive bronchiectasis, and the destructive inflammation that drives CF lung disease.
Patient-derived airway organoids/ALI cultures let researchers test whether an individual's own F508del (or rarer) CFTR alleles respond to a given modulator combination before ever prescribing the drug — a personalized, "n-of-1" functional test that has become essential for patients with genotypes too rare to have been included in pivotal clinical trials.
Originally developed by the Beekman laboratory (Utrecht, Netherlands) using rectal organoids from the Dutch CF biobank, the forskolin-induced swelling (FIS) assay has become the gold-standard functional test for CFTR activity in patient-derived epithelial organoids, and has since been adapted to airway/bronchial organoids. Forskolin raises intracellular cAMP, activating protein kinase A, which phosphorylates the CFTR regulatory domain — any CFTR that has successfully trafficked to the apical membrane opens, chloride and fluid flow into the lumen, and the organoid visibly swells within minutes to hours.
Pharmacology of the assay: • Forskolin (a diterpenoid adenylate cyclase activator) rapidly elevates intracellular cAMP without needing a specific cell-surface receptor, making the assay broadly applicable across organoid types • Elevated cAMP activates protein kinase A (PKA), which phosphorylates multiple serine residues on the CFTR regulatory (R) domain; phosphorylation relieves R-domain auto-inhibition and permits ATP-dependent NBD dimerization that opens the channel pore • Open apical CFTR conducts Cl⁻ (and HCO3⁻) into the lumen; osmotic water follow-through via paracellular and transcellular routes (aquaporins) drives fluid into the closed luminal space of the organoid, increasing hydrostatic pressure and visible cross-sectional area
Quantification: • Time-lapse brightfield or calcein-green fluorescence microscopy every 5–10 minutes for ~60 minutes post-forskolin • Organoid area normalized to t=0 baseline; area-under-the-curve (AUC) of the swelling curve at 60 minutes is the standard summary statistic • Dose-response curves generated by titrating forskolin concentration (typically 0.008–8 µM) to extract an EC50 and maximal swelling — directly proportional to functional CFTR channel density at the membrane
Because FIS swelling scales monotonically with functional CFTR activity, the assay became a powerful predictive tool: • Rectal organoid biobanks (thousands of CF patients, Netherlands and beyond) allow researchers to correlate individual FIS swelling curves with clinical severity, sweat chloride, and — critically — with in-vitro response to candidate CFTR modulators before those drugs are prescribed • For the ~10% of CF patients carrying rare CFTR genotypes never studied in a randomized clinical trial, ex-vivo organoid FIS response to a modulator is often the only evidence available to support (or deny) insurance approval and clinical use • Airway/bronchial ALI-derived organoids extend this logic directly to the lung epithelium of interest, complementing rectal biobank data with tissue-matched functional readouts, including combined measurement of swelling alongside short-circuit current (Ussing chamber) and mucociliary transport metrics in the same culture system.
Small-molecule CFTR modulators fall into two complementary mechanistic classes: correctors (lumacaftor, tezacaftor, elexacaftor) that bind CFTR co-translationally to stabilize NBD1 folding and rescue ER export, and potentiators (ivacaftor) that bind the channel at the membrane to increase its open probability. Trikafta — the triple combination elexacaftor/tezacaftor/ivacaftor, approved by the FDA in 2019 for ages 12+ and extended to ages 6–11 in 2021 — is now eligible for roughly 90% of CF patients carrying at least one F508del allele, and organoid dose-response testing remains central to extending its use to rarer genotypes.
Correctors (Class II rescue): • Type 1 correctors (lumacaftor, tezacaftor) bind NBD1 directly, stabilizing its fold and the NBD1–MSD1/2 interface enough to pass ER quality control and traffic to the Golgi and apical membrane • Elexacaftor is a "next-generation" corrector binding a distinct site (near MSD1), providing additive/synergistic correction when combined with tezacaftor — this is what elevates Trikafta's efficacy well above lumacaftor/ivacaftor (Orkambi) or tezacaftor/ivacaftor (Symdeko) predecessors
Potentiators (Class III rescue): • Ivacaftor binds the channel at the membrane and increases open probability independent of phosphorylation state, boosting Cl⁻ conductance of whatever CFTR (mutant or corrected) has reached the surface • Ivacaftor alone is highly effective for gating mutations (e.g., G551D) but provides minimal benefit to F508del without a corrector first restoring trafficked protein to potentiate
Combined triple therapy restores an estimated 40–50% of wild-type CFTR function in F508del homozygous patients — sufficient to markedly improve mucus hydration, ciliary transport, lung function (ppFEV1), and reduce pulmonary exacerbation frequency and sweat chloride toward the non-CF range.
Preclinical-to-clinical pipeline: • Patient-derived organoids/ALI cultures are treated with corrector for 24–48 hours (allowing time for protein re-folding, trafficking, and membrane insertion) before acute potentiator + forskolin challenge in the FIS assay or Ussing chamber short-circuit current measurement • Dose-response curves (swelling AUC or Isc vs. modulator concentration) generate EC50 and maximal-effect parameters directly comparable across genotypes and patients, informing both drug development and individual treatment decisions • In airway ALI cultures specifically, rescued CFTR activity can be tracked through the full functional cascade: increased periciliary layer hydration → restored cilia-mucus engagement → increased ciliary beat frequency and directional mucus transport velocity — connecting molecular channel rescue back to the tissue-level clearance function that ultimately protects the lung.
The pivotal Phase 3 trial of elexacaftor/tezacaftor/ivacaftor in F508del homozygous patients (Middleton et al., NEJM 2019) reported a mean absolute increase in percent-predicted FEV1 of 14.3 points versus placebo, alongside a 63% reduction in pulmonary exacerbation rate — among the largest treatment effects ever recorded in a CF clinical trial, and a direct clinical validation of the corrector+potentiator mechanism first characterized in organoid and ALI culture systems.